Literature DB >> 24100403

Targeting co-stimulatory pathways: transplantation and autoimmunity.

Mandy L Ford1, Andrew B Adams1, Thomas C Pearson1.   

Abstract

The myriad of co-stimulatory signals expressed, or induced, upon T-cell activation suggests that these signalling pathways shape the character and magnitude of the resulting autoreactive or alloreactive T-cell responses during autoimmunity or transplantation, respectively. Reducing pathological T-cell responses by targeting T-cell co-stimulatory pathways has met with therapeutic success in many instances, but challenges remain. In this Review, we discuss the T-cell co-stimulatory molecules that are known to have critical roles during T-cell activation, expansion, and differentiation. We also outline the functional importance of T-cell co-stimulatory molecules in transplantation, tolerance and autoimmunity, and we describe how therapeutic blockade of these pathways might be harnessed to manipulate the immune response to prevent or attenuate pathological immune responses. Ultimately, understanding the interplay between individual co-stimulatory and co-inhibitory pathways engaged during T-cell activation and differentiation will lead to rational and targeted therapeutic interventions to manipulate T-cell responses and improve clinical outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 24100403      PMCID: PMC4365450          DOI: 10.1038/nrneph.2013.183

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  134 in total

1.  ICOS co-stimulatory receptor is essential for T-cell activation and function.

Authors:  C Dong; A E Juedes; U A Temann; S Shresta; J P Allison; N H Ruddle; R A Flavell
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

2.  Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway.

Authors:  Modesta P Ndejembi; John R Teijaro; Deepa S Patke; Adam W Bingaman; Meena R Chandok; Agnes Azimzadeh; Steven G Nadler; Donna L Farber
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

3.  Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.

Authors:  T Wekerle; J Kurtz; H Ito; J V Ronquillo; V Dong; G Zhao; J Shaffer; M H Sayegh; M Sykes
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

4.  Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell.

Authors:  Patricia A Taylor; Thea M Friedman; Robert Korngold; Randolph J Noelle; Bruce R Blazar
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

6.  Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.

Authors:  Andrew L Mellor; Phillip Chandler; Babak Baban; Anna M Hansen; Brendan Marshall; Jeanene Pihkala; Herman Waldmann; Stephen Cobbold; Elizabeth Adams; David H Munn
Journal:  Int Immunol       Date:  2004-09-06       Impact factor: 4.823

7.  CD8+ Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deficient mice.

Authors:  Bryna E Burrell; Keri Csencsits; Guanyi Lu; Svetlana Grabauskiene; D Keith Bishop
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Authors:  P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

9.  A subtle role for CD2 in T cell antigen recognition.

Authors:  P A van der Merwe
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

10.  Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.

Authors:  Tim A Weaver; Ali H Charafeddine; Avinash Agarwal; Alexandra P Turner; Maria Russell; Frank V Leopardi; Robert L Kampen; Linda Stempora; Mingqing Song; Christian P Larsen; Allan D Kirk
Journal:  Nat Med       Date:  2009-07-05       Impact factor: 53.440

View more
  66 in total

Review 1.  Targeting memory T cells in type 1 diabetes.

Authors:  Mario R Ehlers; Mark R Rigby
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

2.  Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig.

Authors:  I R Badell; G M La Muraglia; D Liu; M E Wagener; G Ding; M L Ford
Journal:  Am J Transplant       Date:  2017-08-14       Impact factor: 8.086

3.  CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.

Authors:  Ekua W Brenu; Timothy J Bartley; Casey M Wright; Emma E Hamilton-Williams
Journal:  Immunol Cell Biol       Date:  2017-06-14       Impact factor: 5.126

4.  Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model.

Authors:  Laura Higginbotham; Dave Mathews; Cynthia A Breeden; Mingqing Song; Alton Brad Farris; Christian P Larsen; Mandy L Ford; Andrew J Lutz; Matthew Tector; Kenneth A Newell; A Joseph Tector; Andrew B Adams
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

Review 5.  New insights into T-cell cosignaling in allograft rejection and survival.

Authors:  Scott M Krummey; Mandy L Ford
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

6.  AAV9-mediated engineering of autotransplanted kidney of non-human primates.

Authors:  S Tomasoni; P Trionfini; N Azzollini; L Zentilin; M Giacca; S Aiello; L Longaretti; E Cozzi; N Baldan; G Remuzzi; A Benigni
Journal:  Gene Ther       Date:  2017-03-27       Impact factor: 5.250

Review 7.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 8.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Inducible Costimulator Contributes to Methicillin-Resistant Staphylococcus aureus Pneumonia.

Authors:  Silvia Pires; Rudy Jacquet; Dane Parker
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

Review 10.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.